Cohance Lifesciences Q3 FY26 Results: Total Income at ₹1462.95 Crore, Net Profit at ₹194.15 Crore
Cohance Lifesciences reported unaudited financial results for the quarter and nine months ended December 31, 2025. Total income for nine months was ₹1462.95 crore. Net profit after tax for nine months was ₹194.15 crore. Quarter ended December 31, 2025, saw total income of ₹481.58 crore and net profit of ₹47.29 crore.
The financial results, particularly the net profit figures, are material information for investors and can influence stock performance.
The company reported positive financial results with a significant net profit for the nine months ended December 31, 2025.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company reported a total income from operations of ₹1462.95 crore for the nine months ended December 31, 2025, compared to ₹2504.43 crore in the same period last year. For the quarter ended December 31, 2025, the total income was ₹481.58 crore.
The net profit for the nine months ended December 31, 2025, after tax and exceptional items, stood at ₹194.15 crore, a significant increase from ₹491.18 crore in the previous year. The net profit for the quarter ended December 31, 2025, was ₹47.29 crore.
Total comprehensive income for the nine months ended December 31, 2025, was ₹190.75 crore. The company's equity share capital remained ₹38.26 crore. The results were approved by the Board of Directors on February 12, 2026, and are available on the company's website and stock exchange websites.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.